<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010394852</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010394852</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Efficacy of Antidepressants as Analgesics</article-title>
<subtitle>A Review</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Dharmshaktu</surname><given-names>Pinky</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Tayal</surname><given-names>Vandana</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kalra</surname><given-names>Bhupinder Singh</given-names></name>
<degrees>MD</degrees>
</contrib>
<aff id="aff1-0091270010394852">Department of Pharmacology, Maulana Azad Medical College, Delhi, India</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0091270010394852">Bhupinder Singh Kalra, Department of Pharmacology, Maulana Azad Medical College, Bahadur shah zafar marg, Delhi, India 110002; e-mail: <email>drbskalra@yahoo.co.in</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>1</issue>
<fpage>6</fpage>
<lpage>17</lpage>
<history>
<date date-type="received">
<day>27</day>
<month>7</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>11</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>Persistent pain disorders are usually not adequately alleviated by nonsteroidal anti-inflammatory drugs or other simple analgesics. Use of antidepressants as adjuvant therapy for the control of persistent pain is currently being practiced in disorders such as fibromyalgia, neuropathic pain, rheumatoid conditions, low back pain, and headache. This review describes the various mechanisms of analgesic activity of antidepressants along with their efficacy and tolerability profiles. Meta-analyses and clinical studies of these agents were retrieved through the use of MEDLINE, Google scholar, and Cochrane databases. Antidepressants are effective in both neuropathic and non-neuropathic pain and have diverse mechanisms independent of their antidepressant effects. Tricyclic antidepressants (amitryptiline, nortryptiline, desipramine) are effective compounds in the treatment of neuropathic pain, fibromyalgia, low back pain, and headaches. Studies are ongoing for the dual serotonin norepinephrine reuptake inhibitors (duloxetine, venlafaxine) in several persistent pain conditions and these may be recommended in neuropathic pain, migraines, and fibromyalgia. Evidence suggests that although the analgesic effects of selective serotonin reuptake inhibitors (fluoxetine, paroxetine, citalopram) are limited and inconsistent, yet they have a superior tolerability profile compared with tricyclic antidepressants.</p>
</abstract>
<kwd-group>
<kwd>neuropathic pain</kwd>
<kwd>antidepressants</kwd>
<kwd>back pain</kwd>
<kwd>fibromyalgia</kwd>
<kwd>headache</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>International Association for the Study of Pain (IASP) defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.<sup><xref ref-type="bibr" rid="bibr1-0091270010394852">1</xref></sup> This suggests that pain is a subjective experience and that the mere presence of physical injury may or may not adequately explain it. Pain can be categorized as noci-ceptive, inflammatory, neuropathic or functional/dysfunctional (eg, of latter include irritable bowel syndrome, fibromyalgia, tension headache etc).<sup><xref ref-type="bibr" rid="bibr2-0091270010394852">2</xref>,<xref ref-type="bibr" rid="bibr3-0091270010394852">3</xref></sup> Persistence of pain is mainly due to activation of multiple pathophysiological mechanisms, leading to hyperexcitability of the somatosensory system.<sup><xref ref-type="bibr" rid="bibr4-0091270010394852">4</xref></sup></p>
<p>In a recent study, it was observed that the age-standardized prevalence of persistent pain conditions was 37.3% in developed countries and 41.1% in developing countries, with back pain and headache being somewhat more common in developing than developed countries.<sup><xref ref-type="bibr" rid="bibr5-0091270010394852">5</xref></sup> Also, a higher prevalence of persistent pain conditions was seen among females and the elderly population.</p>
<p>Persistent pain appears to be associated with the depression-anxiety spectrum of disorders.<sup><xref ref-type="bibr" rid="bibr5-0091270010394852">5</xref></sup> The presence of persistent pain significantly increases the risk of future depression, major depression and anxiety, and vice versa.<sup><xref ref-type="bibr" rid="bibr6-0091270010394852">6</xref></sup> Studies indicate a high concordance of persistent pain and depression.<sup><xref ref-type="bibr" rid="bibr7-0091270010394852">7</xref>–<xref ref-type="bibr" rid="bibr9-0091270010394852">9</xref></sup> It has been seen that 75%–80% of patients with depression suffer from persistent pain conditions such as headache, abdominal pain, neck pain, low back pain.<sup><xref ref-type="bibr" rid="bibr10-0091270010394852">10</xref></sup> Conversely, 20%–40% of patients with fibromyalgia have concurrent depression and 17.5% of patients with persistent spinal pain usually have an associated mood disorder.<sup><xref ref-type="bibr" rid="bibr9-0091270010394852">9</xref>,<xref ref-type="bibr" rid="bibr11-0091270010394852">11</xref></sup> Persistent pain increases the probability of depression, with an adjusted OR (odds ratio) of 1.6.<sup><xref ref-type="bibr" rid="bibr6-0091270010394852">6</xref></sup> In an epidemiological study, it was observed that compared with the prevalence of mood disorders in patients without pain, having pain more than doubled the prevalence of depression (OR 2.3), dysthymia (OR 2.8), anxiety disorder (OR 2.7), agoraphobia or panic disorder (OR 2.1), and social phobia (OR 1.9).<sup><xref ref-type="bibr" rid="bibr6-0091270010394852">6</xref></sup></p>
<sec id="section1-0091270010394852">
<title>Pain Mechanisms</title>
<p>Pain is a complex neurobiological phenomenon with a variety of factors contributing to peripheral and central pain-signaling mechanisms.</p>
<sec id="section2-0091270010394852">
<title>Peripheral Sensory Pathways</title>
<p>Tissue damage and the associated inflammation causes release of number of inflammatory mediators such as prostaglandins (PG) and bradykinin. These agents increase the sensitivity of primary sensory neurons to painful stimuli (hyperalgesia). Strong activation by proinflammatory mediators also drives the opening of voltage gated sodium channels (VGSCs). These channels play a fundamental role in the excitability of neurons in the central and peripheral nervous system,<sup><xref ref-type="bibr" rid="bibr12-0091270010394852">12</xref></sup> and their overexpression is responsible for central and peripheral sensitization. Studies have demonstrated overexpression of VGSCs in neuropathic pain.<sup><xref ref-type="bibr" rid="bibr13-0091270010394852">13</xref>,<xref ref-type="bibr" rid="bibr14-0091270010394852">14</xref></sup></p>
<p>Thus, different types of persistent pain appear to result in long-term neuronal hyperexcitability.<sup><xref ref-type="bibr" rid="bibr15-0091270010394852">15</xref></sup></p>
</sec>
<sec id="section3-0091270010394852">
<title>Central Pathways</title>
<p>Ascending projecting fibers from the dorsal horn in the spinal cord convey sensory information from the periphery to the brain. This provides support for parts of the brain responsible for interpretation of sensory input and mood and their interrelationship in pain perception. Hence, there is an interconnection between persistent pain and affective disorders (eg, depression, anxiety) as discussed previously. Persistence of pain occurs due to central sensitization in which excitatory mediators play a major role.<sup><xref ref-type="bibr" rid="bibr16-0091270010394852">16</xref></sup> Glutamate is the major neurotransmitter whose augmented function at postsynaptic NMDA (<italic>N</italic>-methyl <italic>D</italic>-aspartate) receptors contributes to central sensitization. Also changes in gene expression such as induction of PGE2 contribute to sustained pain after hours and days of injury.</p>
<p>The descending pathways (inhibitory or facilitatory) from supraspinal areas converge at the dorsal horn. Monoaminergic (norepinephrine and serotonin) and opioidergic neurons from descending pathways are inhibitory for pain transmission. In neuropathic pain, persistent pain is thought to be principally due to activation of descending pain facilitatory pathways and deactivation of descending pain inhibitory pathways.<sup><xref ref-type="bibr" rid="bibr7-0091270010394852">7</xref>–<xref ref-type="bibr" rid="bibr11-0091270010394852">11</xref>,<xref ref-type="bibr" rid="bibr17-0091270010394852">17</xref>,<xref ref-type="bibr" rid="bibr18-0091270010394852">18</xref></sup></p>
</sec>
<sec id="section4-0091270010394852">
<title>Dorsal Horn</title>
<p>Convergence of peripheral inputs and descending pathways occurs in the superficial laminae of the spinal cord. The spinal cord controls the transmission of noxious stimuli by the action of inhibitory molecules such as gamma-aminobutyric acid (GABA), endogenous opioids and monoamines. Hyperexcitability of sensory neurons within the dorsal root ganglia and the spinal cord dorsal horn is responsible for persistent pain due to peripheral nerve injury.<sup><xref ref-type="bibr" rid="bibr19-0091270010394852">19</xref>,<xref ref-type="bibr" rid="bibr20-0091270010394852">20</xref></sup> Voltage-gated sodium channel (VGSC) excitation due to noxious input from periphery is responsible for hyperexcitability.</p>
</sec>
</sec>
<sec id="section5-0091270010394852">
<title>Antidepressants as Analgesics</title>
<p>Selected antidepressants suppress pain by diverse mechanisms and are now considered as an essential component of the therapeutic strategy for treatment of many types of persistent pain.<sup><xref ref-type="bibr" rid="bibr21-0091270010394852">21</xref></sup> Their main mechanism of action involves reinforcement of the descending inhibitory pathways by increasing the amount of norepinephrine and serotonin in the synaptic cleft at both supraspinal and spinal levels (<xref ref-type="table" rid="table1-0091270010394852">Table I</xref>). Studies have demonstrated a critical role for VGSCs in many types of chronic pain syndromes because these channels play a fundamental role in the excitability of neurons in the central and peripheral nervous systems. Antidepressants with property of blocking sodium channel have been shown to be effective in suppression of persistent pain signal (<xref ref-type="table" rid="table1-0091270010394852">Table I</xref>).</p>
<table-wrap id="table1-0091270010394852" position="float">
<label>Table I</label>
<caption><p>Mechanism of action of antidepressants as analgesics</p></caption>
<graphic alternate-form-of="table1-0091270010394852" xlink:href="10.1177_0091270010394852-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Mechanism of action</th>
<th align="center">Site of action</th>
<th align="center">TCA</th>
<th align="center">SNRI</th>
<th align="center">SSRI</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reuptake inhibition of monoamine</td>
<td>Serotonin</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="center">+</td>
<td>22,23</td>
</tr>
<tr>
<td/>
<td>Noradrenalin</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="center">−</td>
<td/>
</tr>
<tr>
<td>Receptor antagonism</td>
<td>Adrenergic (alpha-1)</td>
<td align="center">+</td>
<td align="center">−</td>
<td align="center">−</td>
<td>24,25</td>
</tr>
<tr>
<td/>
<td>NMDA</td>
<td align="center">+</td>
<td>+ milnacipran</td>
<td align="center">−</td>
<td>26,27</td>
</tr>
<tr>
<td>Blocker or activator of ion channels</td>
<td>Sodium channel blocker</td>
<td align="center">+</td>
<td>+venlafaxine</td>
<td>(+)only fluoxetine</td>
<td>21,28,29</td>
</tr>
<tr>
<td/>
<td>Calcium channel blocker</td>
<td align="center">+</td>
<td>− duloxetine</td>
<td>(+) citalopram</td>
<td>30</td>
</tr>
<tr>
<td/>
<td>Potassium channel activator</td>
<td align="center">+</td>
<td align="center">?</td>
<td>fluoxetine</td>
<td>31</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="center">?</td>
<td align="center">−</td>
<td/>
</tr>
<tr>
<td>Adenosine</td>
<td>Increase adenosine availability and local release; activation of adenosine A1 receptor</td>
<td>+ amitriptyline</td>
<td align="center">?</td>
<td align="center">?</td>
<td>32</td>
</tr>
<tr>
<td>GABA<sub>B</sub> receptor</td>
<td>Increase GABA<sub>B</sub> receptor function</td>
<td>+ amitriptyline desipramine</td>
<td align="center">?</td>
<td>+ fluoxetine</td>
<td>33</td>
</tr>
<tr>
<td>Opioid receptor binding/opioid-mediated effect</td>
<td>Activation of μ- and δ-opioid receptors</td>
<td align="center">+</td>
<td>+ venlafaxine</td>
<td>+ paroxetine</td>
<td>34,35</td>
</tr>
<tr>
<td>Inflammation</td>
<td>Decrease of PGE2 production</td>
<td align="center">+</td>
<td align="center">?</td>
<td>+ fluoxetine</td>
<td>36</td>
</tr>
<tr>
<td/>
<td>Decrease of TNFα production</td>
<td align="center">+</td>
<td align="center">?</td>
<td align="center">?</td>
<td>37</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010394852">
<p>PGE2 = prostaglandin E2; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; NMDA = N-methyl-D-aspartate; GABA = gamma-Aminobutyric acid; TCA = tricyclic antidepressant; TNFα = tumor necrosis factor-α; + indicates mechanism of action documented in vitro and/or in vivo; + indicates mechanism of action documented in vitro and/or in vivo at high concentration; – indicates no known mechanism of action; ? indicates not investigated/not known. Reproduced with Permission from author (Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. <italic>Drugs</italic>. 2008;68(18):2611-32)<sup><xref ref-type="bibr" rid="bibr38-0091270010394852">38</xref></sup></p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There is increased release of neurotransmitter and augmented function of postsynaptic NMDA glutamate receptors. Also changes in gene expression like induction of PGE2 contribute to central sensitization and are also responsible for sustained pain after hours and days of injury. Antidepressants, by inhibiting NMDA receptors and decreasing PGE2 production, may contribute to an analgesic property (<xref ref-type="table" rid="table1-0091270010394852">Table I</xref>).</p>
<p>Antidepressant drugs have analgesic effects in chronic rheumatic painful states in which nonsteroidal anti-inflammatory drugs (NSAIDs) are not very efficient, such as fibromyalgia.<sup><xref ref-type="bibr" rid="bibr39-0091270010394852">39</xref></sup> Peripheral neuropathic pain is the pain condition for which the greatest amount of evidence for the therapeutic use of antidepressants exists. Different types of peripheral neuropathic pain show similar outcomes except HIV and chemotherapy-associated painful induced neuropathies, spinal cord injury, and phantom limb pain, which do not, in general, respond to these agents.<sup><xref ref-type="bibr" rid="bibr20-0091270010394852">20</xref>,<xref ref-type="bibr" rid="bibr40-0091270010394852">40</xref>–<xref ref-type="bibr" rid="bibr42-0091270010394852">42</xref></sup></p>
<p>Several studies have documented that the analgesic effect is independent of the antidepressant effect and that these agents are effective in patients with persistent pain who do not have concurrent depression.<sup><xref ref-type="bibr" rid="bibr43-0091270010394852">43</xref>–<xref ref-type="bibr" rid="bibr45-0091270010394852">45</xref></sup> Also it has been observed that analgesic action is strongest in antidepressants with mixed-receptor or predominantly noradrenergic activity.<sup><xref ref-type="bibr" rid="bibr46-0091270010394852">46</xref>,<xref ref-type="bibr" rid="bibr47-0091270010394852">47</xref></sup></p>
</sec>
<sec id="section6-0091270010394852">
<title>Evidence for Efficacy of Antidepressants in <italic>Persistent</italic> Pain</title>
<p>Several open-label studies, randomized controlled clinical trials, meta-analyses, and systematic reviews have confirmed the clinical efficacy of selected antidepressants in persistent pain conditions (<xref ref-type="table" rid="table2-0091270010394852">Table II</xref>).</p>
<table-wrap id="table2-0091270010394852" position="float">
<label>Table II</label>
<caption><p>Evidence for Efficacy of Antidepressants in Various Disease Conditions</p></caption>
<graphic alternate-form-of="table2-0091270010394852" xlink:href="10.1177_0091270010394852-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Disease Condition</th>
<th align="center">Treatment</th>
<th align="center">Study design</th>
<th align="center">Total No. of Patients (Active, Placebo)</th>
<th align="center">Outcome</th>
<th align="center">NNT(C.I)/Effect Size</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="7">Neuropathic pain</td>
</tr>
<tr>
<td>Post herpetic neuralgia</td>
<td>Nortriptyline</td>
<td>Cross-over, DB, RCT</td>
<td>56</td>
<td>TCA&gt;Pl</td>
<td>NNT: 4.0 (2.6, 8.9)</td>
<td>48</td>
</tr>
<tr>
<td>Painful polyneuropathy</td>
<td>Imipramine</td>
<td>Cross-over, DB, RCT</td>
<td>29</td>
<td>Imi&gt;Pl</td>
<td>NNT: 2.4 (1.6, 4.8)</td>
<td>49</td>
</tr>
<tr>
<td/>
<td>Fluoxetine</td>
<td>Cross-over, DB, RCT</td>
<td>46</td>
<td>Flu = pl</td>
<td>15.3 (3.7, ∞)</td>
<td>50</td>
</tr>
<tr>
<td/>
<td>Venlafaxine</td>
<td>Parallel, DB RCT</td>
<td>244(163,81)</td>
<td>Ven&gt;Pl</td>
<td>NNT: 6.9 (3.7, 58.6)</td>
<td>51</td>
</tr>
<tr>
<td>HIV-neuropathy</td>
<td>Amitryptiline</td>
<td>Parallel, DB, RCT</td>
<td>97(47,50)</td>
<td>Ami = Pl</td>
<td>NNT: 50 (4, ∞)</td>
<td>40</td>
</tr>
<tr>
<td>Painful diabetic neuropathy</td>
<td>Duloxetine</td>
<td>Parallel, DB, RCT</td>
<td>457(115, 348)</td>
<td>Dul&gt;Pl</td>
<td>N.A</td>
<td>52,53</td>
</tr>
<tr>
<td/>
<td>TCAs:Amitryptline, Desipramine, Imipramine, Doxepin,Nortryptline<break/>SSRIs:Citalopram, Fluvoxamine, Paroxetine,Fluoxotine, Sertraline<break/>SNRI: Venlafaxine</td>
<td>Meta-analysis</td>
<td>3293 (in 61 studies)</td>
<td>TCA&gt;Pl, SSRI&gt;Pl, SRI&lt;TCA, SNRI&gt;PL</td>
<td>NNT: TCA 3.6 (3, 4.5) Ven 3.1 (2.2, 5.1)</td>
<td>45</td>
</tr>
<tr>
<td colspan="7">Fibromyalgia</td>
</tr>
<tr>
<td/>
<td>Citalopram</td>
<td>Parallel, DB, RCT</td>
<td>43(22,21)</td>
<td>Cit = Pl</td>
<td>NA</td>
<td>39,54</td>
</tr>
<tr>
<td/>
<td>Amitryptiline, Nortryptiline</td>
<td>Parallel, DB, RCT</td>
<td>118(40,38,40)</td>
<td>Ami&gt;Pl, Nor&gt;Pl, Ami = Nor</td>
<td>ES: Ami 0.54 [0.06, 1.02]<break/>Nor 0.13 [-0.35, 0.60]</td>
<td>39,55</td>
</tr>
<tr>
<td/>
<td>Fluoxetine</td>
<td>Parallel, DB, RCT</td>
<td>60(30,30)</td>
<td>Flu&gt;Pl</td>
<td>ES: 0.9 (0.33, 1.48)</td>
<td>56</td>
</tr>
<tr>
<td/>
<td>Duloxetine</td>
<td>Parallel, DB, RCT</td>
<td>207(104,103)</td>
<td>Dul&gt;Pl</td>
<td>ES: 0.22 [-0.06, 0.49]</td>
<td>17</td>
</tr>
<tr>
<td/>
<td>Milnacipran</td>
<td>Parallel, DB, RCT</td>
<td>888(665,223)</td>
<td>Mil&gt;Pl</td>
<td>ES: 0.56 [0.09, 1.03]</td>
<td>57</td>
</tr>
<tr>
<td/>
<td>TCAs: Amitryptline, Clomipramine, Maprotiline<break/>SSRIs: Citalopram, Fluoxotine</td>
<td>Meta-analysis</td>
<td>700 (in 13 studies)</td>
<td>TCA&gt;Pl<break/>SSRI&gt;Pl</td>
<td>NNT: AD 4 (2.9, 6.3)</td>
<td>58</td>
</tr>
<tr>
<td colspan="7">Low back pain</td>
</tr>
<tr>
<td/>
<td>Paroxetine</td>
<td>Cross-over, DB, RCT</td>
<td>92</td>
<td>Par = Pl</td>
<td>ES not calculable</td>
<td>59</td>
</tr>
<tr>
<td/>
<td>Bupropion</td>
<td>Cross-over, DB, RCT</td>
<td>44</td>
<td>Bup = Pl</td>
<td>ES not calculable</td>
<td>60</td>
</tr>
<tr>
<td/>
<td>TCAs: Amitryptline, Imipramine, Nortryptiline, Maprotiline<break/>SARI: Trazodone<break/>SSRI: Paroxetine</td>
<td>Systematic Review</td>
<td>450 (in 7 studies)</td>
<td>TCA&gt;Pl, SARI=Pl, SSRI = Pl</td>
<td>NA</td>
<td>61</td>
</tr>
<tr>
<td colspan="7">Rheumatoid Arthritis</td>
</tr>
<tr>
<td/>
<td>Imipramine</td>
<td>Parallel, DB, RCT</td>
<td>59(30,29)</td>
<td>Imi = Pl</td>
<td>ES not calculable</td>
<td>39,62</td>
</tr>
<tr>
<td/>
<td>Dothiepin</td>
<td>Parallel, DB, RCT</td>
<td>48 (25,23)</td>
<td>Dot&gt;Pl</td>
<td>ES: 0.72 (0.14, 1.34)</td>
<td>39,63</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>Amitryptiline</td>
<td>Parallel, DB, RCT</td>
<td>88 (44,44)</td>
<td>Ami&gt;Pl</td>
<td>ES: 0 (- 0.35, 0.48)</td>
<td>64</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0091270010394852">
<p>DB = double-blind; RCT = randomized controlled trial; CI = confidence interval; ES = Effect size; Pl = placebo; NNT = Numbers Needed to Treat to obtain 1 patient with more than 50% pain relief; TCA = tricyclic antidepressant; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin norepinephrine reuptake inhibitor; SARI = serotonin antagonist reuptake inhibitor; &gt; indicates more effective than; = indicates as effective as; NA = no available NNT due to insufficient data; ES = effect size.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section7-0091270010394852">
<title>Tricyclic Antidepressants</title>
<p>Evidence gathered over several decades suggests that tricyclic antidepressants (TCAs) are the “gold standard” antidepressants for the treatment of persistent neuropathic pain.<sup><xref ref-type="bibr" rid="bibr65-0091270010394852">65</xref>,<xref ref-type="bibr" rid="bibr66-0091270010394852">66</xref></sup> Most of the randomized, controlled trials (RCTs) have been performed in patients with postherpetic neuralgia and painful polyneuropathy (especially diabetic neuropathy) in which level 1 evidence (good quality-patient oriented evidence) exists for amitriptyline.<sup><xref ref-type="bibr" rid="bibr65-0091270010394852">65</xref></sup> The etiologies of central neuropathic pain include stroke, spinal cord injury, and multiple sclerosis. According to recent guidelines, there is level 2 evidence (limited quality-patient oriented evidence) for the use of TCAs in central neuropathic pain.<sup><xref ref-type="bibr" rid="bibr67-0091270010394852">67</xref></sup> For example amitriptyline has been found to be superior to placebo (<italic>P</italic> value &lt; .05) in post stroke pain but not in the neuropathic pain of spinal cord injury.<sup><xref ref-type="bibr" rid="bibr20-0091270010394852">20</xref>,<xref ref-type="bibr" rid="bibr68-0091270010394852">68</xref></sup></p>
<p>The number needed to treat (ie, NNT [the number of patients who have to be treated to reduce pain intensity by 50% in 1 patient]) ranges from 2 to 4 for TCAs in neuropathic pain (<xref ref-type="table" rid="table2-0091270010394852">Table II</xref>).<sup><xref ref-type="bibr" rid="bibr69-0091270010394852">69</xref></sup> Fibromyalgia is another condition in which efficacy of TCAs is reasonably well-established.<sup><xref ref-type="bibr" rid="bibr55-0091270010394852">55</xref>,<xref ref-type="bibr" rid="bibr70-0091270010394852">70</xref>–<xref ref-type="bibr" rid="bibr84-0091270010394852">84</xref></sup> Most studies have reported that TCAs were effective at doses lower than those needed for the treatment of depression.<sup><xref ref-type="bibr" rid="bibr80-0091270010394852">80</xref>,<xref ref-type="bibr" rid="bibr83-0091270010394852">83</xref></sup> The analgesic effect size (ES) (difference between 2 means [antidepressant analgesic effect - placebo analgesic effect] divided by the pooled estimate standard deviation) of TCAs ranged from 0.23 to 1.34 in fibromyalgia. Effect size is a measure of the strength of the relationship between 2 variables in a sample. In meta-analysis, effect size is concerned with different studies and then combines all the studies into single analysis. Effect size is also categorized as small, medium and large. Range of 0.2 to 0.3 might be a “small” effect, around 0.5 a “medium” effect, and 0.8 to infinity, a “large” effect.</p>
<p>A meta-analysis by Arnold and colleagues included 9 RCTs with TCAs (amitriptyline, dosulepin) which showed significant clinical responses in approximately 30% of patients with fibromyalgia with improvement of all outcomes (fatigue, sleep, pain, stiffness, tenderness).<sup><xref ref-type="bibr" rid="bibr85-0091270010394852">85</xref></sup> However, greater effect was seen on sleep disorders and fatigue than on pain, indicating that TCAs have only a moderate analgesic effect in fibromyalgia.<sup><xref ref-type="bibr" rid="bibr78-0091270010394852">78</xref>,<xref ref-type="bibr" rid="bibr80-0091270010394852">80</xref>,<xref ref-type="bibr" rid="bibr83-0091270010394852">83</xref></sup></p>
<p>In low back pain (LBP), TCAs have been the most frequently-tested antidepressants and, according to the guidelines of the American Pain Society and American College of Physicians, TCAs are effective for pain relief in LBP.<sup><xref ref-type="bibr" rid="bibr86-0091270010394852">86</xref></sup> Their analgesic effect has been reported to be similar to that of NSAIDs.<sup><xref ref-type="bibr" rid="bibr87-0091270010394852">87</xref></sup> Studies with amitryptiline, nortriptyline, and maprotiline demonstrated analgesic ESs ranging from 0.45 to 0.64.<sup><xref ref-type="bibr" rid="bibr88-0091270010394852">88</xref>–<xref ref-type="bibr" rid="bibr90-0091270010394852">90</xref></sup> A meta analysis by Salerno and colleagues revealed that antidepressants had a small but statistically significant effect in reducing LBP when compared with placebo. Patients treated with antidepressants experienced a small but significant improvement of 0.41 (95% confidence interval [CI], 0.22–0.61) in the standardized mean difference for pain severity.<sup><xref ref-type="bibr" rid="bibr46-0091270010394852">46</xref></sup> In a systematic review, Staiger and colleagues reported that antidepressants which inhibit NE reuptake (amitriptyline, imipramine, nortriptyline, maprotiline) were more effective in reducing pain than agents that do not inhibit norepinephrine reuptake (<xref ref-type="table" rid="table2-0091270010394852">Table II</xref>).<sup><xref ref-type="bibr" rid="bibr61-0091270010394852">61</xref></sup></p>
<p>Few studies exist of TCAs for the treatment of pain due to inflammatory rheumatic diseases. Those that exist are of poor methodological quality. In a study, involving 1001 older adults with concurrent depression and arthritis, use of TCAs resulted in a significantly lower mean score for pain intensity ([5.62 versus 6.15]; between-group difference, -0.53) (<italic>P</italic> = .009) relative to control patients. Overall improvements in health-related and quality of life was also observed.<sup><xref ref-type="bibr" rid="bibr91-0091270010394852">91</xref></sup> In a placebo controlled trial, dothiepin was found to be effective in relieving pain, disability and reducing the duration of early morning stiffness in outpatients with rheumatoid arthritis (<xref ref-type="table" rid="table2-0091270010394852">Table II</xref>). Results of these studies have suggested that TCAs have weak analgesic effects in patients with RA, with or without depressive symptoms.<sup><xref ref-type="bibr" rid="bibr62-0091270010394852">62</xref>,<xref ref-type="bibr" rid="bibr92-0091270010394852">92</xref></sup> In ankylosing spondylitis, amitriptyline may be useful in reducing several symptoms (pain, fatigue and sleep disorders) but this has not been confirmed with other TCAs.<sup><xref ref-type="bibr" rid="bibr93-0091270010394852">93</xref></sup></p>
<p>For chronic headaches, meta-analyses have demonstrated that patients receiving antidepressants were twice as likely to report headache improvement (rate ratio [RR]: 2.0; 95% CI: 1.6 to 2.4.<sup><xref ref-type="bibr" rid="bibr94-0091270010394852">94</xref>–<xref ref-type="bibr" rid="bibr96-0091270010394852">96</xref></sup> The beneficial effect of TCAs was the largest of all antidepressants. Because 31% (95% CI: 23% to 40%) more treated patients improved than those receiving placebo, clinicians would need to treat 3.2 patients for 1 patient to improve. Although TCAs appear to be the most effective antidepressant analgesics for persistent pain conditions, their poor tolerability profile (discussed below) and need for careful dose titration are major limitations.</p>
<p>Before starting TCA treatment, postural blood pressure readings and an electrocardiogram (ECG) (for QTc interval measurement) should be done. TCAs should be initiated at low dosages—10 to 25 mg in a single dose at bedtime—and then titrated every 3 to 7 days by 10 to 25 mg/d as tolerated to decrease adverse effects and increase patient adherence to treatment. TCAs should be titrated to maximum dosages of 75 to 150 mg/d as tolerated. If serum drug concentrations (SDCs) of approximately 100 ng/mL of the parent drug and its metabolite are not found at daily dosages of 100 to 150 mg, titration can be continued further with caution. SDCs of &gt;500 ng/mL (of the parent drug and its metabolite) are associated with toxicity, and for dose titration higher than 100 to 150 mg/d, SDC should be monitored and an ECG redone. An adequate trial of a TCA should last 6 to 8 weeks, with at least 1 to 2 weeks being at the maximum tolerated dosage.</p>
</sec>
<sec id="section8-0091270010394852">
<title>Selective Serotonin Reuptake Inhibitors</title>
<p>Selective serotonin reuptake inhibitors (SSRIs) are better tolerated but are inferior to TCAs in controlling persistent pain due to diabetic neuropathy and fibromyalgia.<sup><xref ref-type="bibr" rid="bibr50-0091270010394852">50</xref>,<xref ref-type="bibr" rid="bibr54-0091270010394852">54</xref>,<xref ref-type="bibr" rid="bibr56-0091270010394852">56</xref>,<xref ref-type="bibr" rid="bibr97-0091270010394852">97</xref>–<xref ref-type="bibr" rid="bibr102-0091270010394852">102</xref></sup> Five studies comparing SSRIs with placebo have found them to be superior to placebo for relieving neuropathic pain.<sup><xref ref-type="bibr" rid="bibr50-0091270010394852">50</xref>,<xref ref-type="bibr" rid="bibr103-0091270010394852">103</xref>–<xref ref-type="bibr" rid="bibr106-0091270010394852">106</xref></sup> In fibromyalgia, fluoxetine (ES: 1.08) is reported to have greater analgesic activity than citalopram (ES: 0.45) and paroxetine (ES: 0.19).<sup><xref ref-type="bibr" rid="bibr39-0091270010394852">39</xref></sup></p>
<p>No analgesic benefit of SSRIs (paroxetine) has been observed in low back pain.<sup><xref ref-type="bibr" rid="bibr53-0091270010394852">53</xref></sup> Therefore evidence does not support the use of SSRIs in LBP. There is no evidence for the use of SSRIs in rheumatoid arthritis and osteoarthritis.<sup><xref ref-type="bibr" rid="bibr39-0091270010394852">39</xref></sup> In migraine or tension type headache, meta-analysis has shown that SSRIs do not adequately reduce headache global severity index compared with placebo after 8 weeks of treatment.<sup><xref ref-type="bibr" rid="bibr107-0091270010394852">107</xref></sup> Also, none of the outcome measures (main outcome measures such as headache frequency, severity, duration and secondary outcome measures such as tolerability, use of other analgesics, quality of life and mood) favored SSRIs. However, given the limitations of the available studies (small sample sizes, short follow-up duration, methodological limitations), there is a need to further investigate the effects of SSRIs in these conditions.</p>
</sec>
<sec id="section9-0091270010394852">
<title>Serotonin Norepinephrine Reuptake Inhibitors</title>
<p>Venlafaxine is 1 of the most investigated antidepressant drugs in pain management. It is effective in the treatment of painful peripheral diabetic neuropathy.<sup><xref ref-type="bibr" rid="bibr108-0091270010394852">108</xref></sup> In neuropathic pain venlafaxine (75 to 225 mg/day) has an NNT of 3.1, which is similar to NNT values seen with TCAs.<sup><xref ref-type="bibr" rid="bibr45-0091270010394852">45</xref></sup> Another study has shown that in neuropathic pain, venlafaxine is as effective as TCAs with the added advantage of absence of intolerable side effects.<sup><xref ref-type="bibr" rid="bibr109-0091270010394852">109</xref></sup> Venlafaxine is often suggested as a second-line drug after other therapies fail (NSAIDs, other antidepressants).<sup><xref ref-type="bibr" rid="bibr67-0091270010394852">67</xref></sup></p>
<p>Recent studies of fibromyalgia have focused on newer antidepressants such as venlafaxine,<sup><xref ref-type="bibr" rid="bibr110-0091270010394852">110</xref>,<xref ref-type="bibr" rid="bibr111-0091270010394852">111</xref></sup> duloxetine,<sup><xref ref-type="bibr" rid="bibr17-0091270010394852">17</xref>,<xref ref-type="bibr" rid="bibr112-0091270010394852">112</xref></sup> and milnacipran<sup><xref ref-type="bibr" rid="bibr57-0091270010394852">57</xref></sup> (<xref ref-type="table" rid="table2-0091270010394852">Table II</xref>). Duloxetine and milnacipran have been found to be similarly effective against the pain of fibromyalgia. These treatments were significantly more effective than placebo, not only against pain, but also for function, clinical global impression of change (assessed both by the patient and the physician), sleep and fatigue. In a 12-week study in 15 patients with fibromyalgia, venlafaxine therapy produced significant improvement in the mean intensity of pain (<italic>P</italic> = .0001) and in the disability caused by fibromylagia (<italic>P</italic> = .0001).<sup><xref ref-type="bibr" rid="bibr110-0091270010394852">110</xref></sup></p>
<p>In a 12-week randomized, double-blind, placebo-controlled trial, duloxetine produced significantly greater reductions in Brief Pain Inventory average pain severity scores (<italic>P</italic> = .008), Brief Pain Inventory average interference from pain scores (<italic>P</italic> = .004), number of tender points (<italic>P</italic> = .002), and FIQ stiffness scores (<italic>P</italic> = .048), and had significantly greater improvement in mean tender point pain threshold (<italic>P</italic> = .002) than did placebo.<sup><xref ref-type="bibr" rid="bibr17-0091270010394852">17</xref></sup> Milnacipran was studied in a double-blind, placebo-controlled trial and was found to be associated with significant improvements in pain after 1 week of treatment (100 mg/d: <italic>P</italic> = .004; 200 mg/d: <italic>P</italic> = .04) compared with placebo.<sup><xref ref-type="bibr" rid="bibr113-0091270010394852">113</xref></sup></p>
<p>There is no published evidence for the efficacy of serotonin norepinephrine reuptake inhibitors (SNRIs) for low back pain. Venlafaxine is effective in reducing the frequency of migraine attacks and is well tolerated.<sup><xref ref-type="bibr" rid="bibr114-0091270010394852">114</xref></sup> Venlafaxine and amitriptyline have been found to have similar effects in migraine prophylaxis.<sup><xref ref-type="bibr" rid="bibr115-0091270010394852">115</xref></sup></p>
</sec>
<sec id="section10-0091270010394852">
<title>Miscellaneous Antidepressants as Analgesics</title>
<p>Very few studies, all having inconsistent results, are available for older antidepressants in persistent pain conditions.</p>
<p>Mianserin (a noradrenergic and specific serotonergic antidepressant) was shown to increase the antinociceptive effect of various analgesic agents in an animal model.<sup><xref ref-type="bibr" rid="bibr116-0091270010394852">116</xref></sup> However, in a double-blind, cross-over study in humans, mianserin showed no analgesic effect in patients with diabetic neuropathy.<sup><xref ref-type="bibr" rid="bibr117-0091270010394852">117</xref></sup> Similarly, mirtazapine, an analogue of mianserin, was effective in a rat model of neuropathic pain<sup><xref ref-type="bibr" rid="bibr118-0091270010394852">118</xref></sup> but was not found efficacious in patients with chronic pain with concomitant depression, although it was well tolerated.<sup><xref ref-type="bibr" rid="bibr119-0091270010394852">119</xref></sup> Presently, mirtazapine is being studied (Phase 4) in fibromylagia and chronic pain (clinicalTrials.gov identifier NCT00919295, NCT01119924).</p>
<p>Trazodone (a selective serotonin reuptake inhibitor and a selective 5-HT2 antagonist) was found to be ineffective in decreasing pain in a double-blind, placebo-controlled study of patients with chronic low back pain.<sup><xref ref-type="bibr" rid="bibr113-0091270010394852">113</xref></sup> Nefazodone (a serotonin-norepinephrine-dopamine reuptake inhibitor and 5-HT2 antagonist) has only been tested in animals and was shown to produce analgesia and potentiate the Mu1 and Mu2 receptor-related analgesic effect of morphine.<sup><xref ref-type="bibr" rid="bibr120-0091270010394852">120</xref></sup> Also, nefazodone is not recommended because of potential hepatotoxicity.</p>
</sec>
</sec>
<sec id="section11-0091270010394852">
<title>Adverse Effects of Antidepressants</title>
<p>The adverse-effects of antidepressants are primarily related to their pharmacological properties.<sup><xref ref-type="bibr" rid="bibr121-0091270010394852">121</xref>,<xref ref-type="bibr" rid="bibr122-0091270010394852">122</xref></sup> TCAs will cause adverse-effects in 30%–100% of patients treated for painful conditions.<sup><xref ref-type="bibr" rid="bibr123-0091270010394852">123</xref>,<xref ref-type="bibr" rid="bibr124-0091270010394852">124</xref></sup> The anticholinergic activity of TCAs results in urinary retention, constipation, dry mouth, drowsiness, blurred vision, tachycardia, memory disorders, and confusion, which can occur in more than 60% of patients with persistent pain.<sup><xref ref-type="bibr" rid="bibr125-0091270010394852">125</xref></sup> Blockade of alpha 1-noradrenergic receptors lead to orthostatic hypotension, tachycardia and dizziness. Trembling and impotence occur due to norepinephrine reuptake inhibition. The blockade of histaminic H1 receptors may result in sedation, somnolence and weight gain. In addition, TCAs also have type 1 antiarrhythmic action and potently inhibit sodium channels which explains their cardiotoxic potential expressed as QTc interval prolongation even with therapeutic doses, especially when patients are taking other drugs with the same electrophysiologic properties.<sup><xref ref-type="bibr" rid="bibr126-0091270010394852">126</xref>,<xref ref-type="bibr" rid="bibr127-0091270010394852">127</xref></sup> Thus it is recommended that TCAs should be prescribed, with caution, in patients with arteriosclerotic cardiovascular disease or ventricular conduction abnormalities. The first generation TCA, desipramine has the least anticholinergic and sedative adverse effects. Thus, it may be considered as an alternative in patients unable to tolerate amitriptyline or imipramine.</p>
<p>SSRIs are better tolerated than TCAs since they are devoid of anticholinergic, antihistaminic, anti-adrenergic, and cardiac side effects.<sup><xref ref-type="bibr" rid="bibr52-0091270010394852">52</xref>,<xref ref-type="bibr" rid="bibr94-0091270010394852">94</xref></sup> The main adverse effects of SSRIs are due to enhanced actions of serotonin in the periphery and the central nervous system (CNS). Gastrointestinal side effects are prominent and include nausea, gastric discomfort, vomiting, anorexia, and diarrhea. Other troublesome effects include decreased libido, delayed orgasm, hyperhidrosis, somnolence or insomnia, drowsiness, fatigue, and weight gain.<sup><xref ref-type="bibr" rid="bibr67-0091270010394852">67</xref></sup></p>
<p>Numerous case reports suggest that SSRIs may cause syndrome of inappropriate antidiuretic hormone secretion (SIADH) characterized by hyponatremia, which may be fatal if severe.<sup><xref ref-type="bibr" rid="bibr128-0091270010394852">128</xref></sup> SIADH is more likely in those who are elderly or take diuretics. An increased risk of bleeding, particularly gastrointestinal blood loss, occurs due to impairment of platelet function by SSRIs. The most commonly-reported severe adverse effect following SSRI overdose or drug–drug interactions resulting in high concentration of serotonin is serotonin syndrome, characterized by a clinical triad of cognitive, autonomic, and somatic effects: headache, agitation, mental confusion, sweating, hyperthermia, hypertension, tachycardia, diarrhea, myoclonus, tremor, hallucinations, and coma.<sup><xref ref-type="bibr" rid="bibr129-0091270010394852">129</xref></sup></p>
<p>SNRIs also elevate serum and central serotonin concentration and, therefore share many of the same side effects as SSRIs. The most frequent adverse events with duloxetine are nausea, vomiting, constipation, somnolence, dry mouth, hyperhidrosis, anorexia, and weakness. Venlafaxine is associated with adverse CNS and somatic symptoms such as agitation, diarrhea, increased liver enzymes, hypertension, and hyponatremia but the extended-release formulation seems to be far better tolerated, with the main side-effect being mild gastrointestinal disturbances. Milnacipran is associated with nausea, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, vomiting, palpitations, tachycardia, dry mouth, and hypertension.<sup><xref ref-type="bibr" rid="bibr57-0091270010394852">57</xref></sup></p>
</sec>
<sec id="section12-0091270010394852">
<title>Guidelines</title>
<p>The first-line antidepressant for pain is the TCA, initiated at low doses and then increased to the maximum tolerated dose (<xref ref-type="table" rid="table3-0091270010394852">Table III</xref>). As per the American Society of Anesthesiologists (ASA) guidelines (2010), TCAs and SNRIs should be used as part of a multimodal strategy (ablative techniques, neural blocks, epidural steroids, intrathecal drug therapy, acupuncture, etc.) for patients with persistent pain. SNRIs are safer than TCAs in patients with preexisting cardiac disease. Selective serotonin reuptake inhibitors may be considered but only for the treatment of diabetic neuropathy.<sup><xref ref-type="bibr" rid="bibr132-0091270010394852">132</xref></sup></p>
<table-wrap id="table3-0091270010394852" position="float">
<label>Table III</label>
<caption><p>Recommendations for use of antidepressants in persistent pain conditions.</p></caption>
<graphic alternate-form-of="table3-0091270010394852" xlink:href="10.1177_0091270010394852-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Neuropathic pain<sup><xref ref-type="bibr" rid="bibr130-0091270010394852">130</xref></sup></th>
<th align="center">Fibromyalgia<sup><xref ref-type="bibr" rid="bibr131-0091270010394852">131</xref></sup></th>
<th align="center">Low back pain<sup><xref ref-type="bibr" rid="bibr86-0091270010394852">86</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>TCAs and SNRIs are first-line medications.<break/>Opioid analgesics are second-line drugs except for neuropathic pain due to cancer where they are considered as first-line.<break/>SSRIs are considered as third-line medications.</td>
<td>TCAs are preferred initial therapy. SNRIs may be considered if TCAs fail.<break/>Very limited and inconsistent results were obtained with SSRIs.</td>
<td>Acetaminophen or nonsteroidal anti-inflammatory drugs are first-line medication.<break/>TCAs have also been shown effective.<break/>SSRI class and trazodone are not effective, while there is no evidence for efficacy of SNRIs for low back pain.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0091270010394852">
<p>TCA = tricyclic antidepressant; SNRI = serotonin norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor;</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section13-0091270010394852">
<title>Conclusion</title>
<p>Persistent pain is not just a nociceptive physical experience but also involves affect, cognition, behavior, or social relations. Thus a holistic approach to persistent pain treatment should take into account all these aspects. Total pain alleviation is the prime goal of pain management. However, in reality, in most cases, it can often only be reduced to a more tolerable level.</p>
<p>Effectiveness rather than efficacy should be the major parameter for establishing the true benefit from analgesic drug therapy. Hence, management of any form of persistent pain requires not only a reduction in pain intensity but also improvement of quality of life (ie, improved sleep, mood, work, social and recreational capacities). These are now increasingly being measured in clinical trials. Antidepressants are complex drugs with multiple actions. Even within a class, different intensities of actions are observed, these accounting for differential actions and side effects. Whether antidepressants can improve the affective component of pain, in addition to alleviating its somatosensory component, is a controversial subject and a challenge in clinical research.</p>
<p>Neuropathic pain is most responsive to the analgesic activities of antidepressants. TCAs are most effective and are considered to be as first-line agents while SNRIs are second-line agents for the treatment of neuropathic pain. However, the effectiveness of the SSRIs is limited in most types of persistent pain. Among rheumatologic conditions, fibromyalgia is the most suitable for treatment with antidepressants since classical analgesics are not very effective. TCAs and SNRIs should be preferred. SSRIs are less effective but better tolerated than TCAs in fibromyalgia.</p>
<p>For other persistent pain indications, such as low back pain, TCAs are preferred over SSRIs, which seem to be less effective and SNRIs, which are yet to be tested. However, in rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis, there are no validated data supporting the use of antidepressants for pain management.</p>
<p>Choice of drug treatment of persistent pain, including antidepressants, should be based on the results of head-to-head, adequately-sized, comparative trials but in their absence, choice should be made based on comparisons of NNT, and ES parameters from placebo-controlled trials. In conclusion, further evidence based research into safety and efficacy is needed, especially for the less-studied newer antidepressants.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010394852">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Merskey</surname><given-names>H</given-names></name>
<name><surname>Bogduk</surname><given-names>N</given-names></name>
</person-group>, eds. <source>Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms</source>. <edition>2nd ed.</edition> <publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>IASP Press</publisher-name>; <year>1994</year>.</citation>
</ref>
<ref id="bibr2-0091270010394852">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouhassira</surname><given-names>D</given-names></name>
</person-group>. <article-title>Definition and classification of neuropathic pain [in French]</article-title>. <source>Presse Med</source>. <year>2008</year>;<volume>37</volume>:<fpage>311</fpage>-<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010394852">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woolf</surname><given-names>CJ</given-names></name>
<name><surname>Decosterd</surname><given-names>I</given-names></name>
</person-group>. <article-title>Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients</article-title>. <source>Pain</source>. <year>1999</year>;(<issue>Suppl 6</issue>):<fpage>S141</fpage>-<lpage>S147</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010394852">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woolf</surname><given-names>CJ</given-names></name>
</person-group>. <article-title>Pain: moving from symptom control toward mechanism-specific pharmacologic management</article-title>. <source>Ann Intern Med</source>. <year>2004</year>;<volume>140</volume>:<fpage>441</fpage>-<lpage>451</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010394852">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsang</surname><given-names>A</given-names></name>
<name><surname>Von Korff</surname><given-names>M</given-names></name>
<name><surname>Lee</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders</article-title>. <source>J Pain</source>. <year>2008</year>;<volume>9</volume>:<fpage>883</fpage>-<lpage>891</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010394852">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tunks</surname><given-names>ER</given-names></name>
<name><surname>Crook</surname><given-names>J</given-names></name>
<name><surname>Weir</surname><given-names>R</given-names></name>
</person-group>. <article-title>Epidemiology of chronic pain with psychological comorbidity: prevalence, risk, course, and prognosis</article-title>. <source>Can J Psychiatry</source>. <year>2008</year>;<volume>53</volume>:<fpage>224</fpage>-<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010394852">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mc Williams</surname><given-names>LA</given-names></name>
<name><surname>Cox</surname><given-names>BJ</given-names></name>
<name><surname>Enns</surname><given-names>MW</given-names></name>
</person-group>. <article-title>Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample</article-title>. <source>Pain</source>. <year>2003</year>;<volume>106</volume>:<fpage>127</fpage>-<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010394852">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mc Williams</surname><given-names>LA</given-names></name>
<name><surname>Goodwin</surname><given-names>RD</given-names></name>
<name><surname>Cox</surname><given-names>BJ</given-names></name>
</person-group>. <article-title>Depression and anxiety associated with three pain conditions: results from a nationally representative sample</article-title>. <source>Pain</source>. <year>2004</year>;<volume>111</volume>:<fpage>77</fpage>-<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010394852">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Von Korff</surname><given-names>M</given-names></name>
<name><surname>Crane</surname><given-names>P</given-names></name>
<name><surname>Lane</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication</article-title>. <source>Pain</source>. <year>2005</year>;<volume>113</volume>:<fpage>331</fpage>-<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010394852">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirmayer</surname><given-names>LJ</given-names></name>
<name><surname>Robbins</surname><given-names>JM</given-names></name>
<name><surname>Dworkind</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Somatization and the recognition of depression and anxiety in primary care</article-title>. <source>Am J Psychiatry</source>. <year>1993</year>;<volume>150</volume>:<fpage>734</fpage>-<lpage>741</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010394852">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hudson</surname><given-names>JL</given-names></name>
<name><surname>Hudson</surname><given-names>MS</given-names></name>
<name><surname>Pliner</surname><given-names>LF</given-names></name>
<etal/>
</person-group>. <article-title>Fibromyalgia and major affective disorder: a controlled phenomenology and family history study</article-title>. <source>Am J Psychiatry</source>. <year>1985</year>;<volume>142</volume>:<fpage>441</fpage>-<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010394852">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cummins</surname><given-names>TR</given-names></name>
<name><surname>Sheets</surname><given-names>PL</given-names></name>
<name><surname>Waxman</surname><given-names>SG</given-names></name>
</person-group>. <article-title>The roles of sodium channels in nociceptive: implications for mechanisms of pain</article-title>. <source>Pain</source>. <year>2007</year>;<volume>131</volume>:<fpage>243</fpage>-<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010394852">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berta</surname><given-names>T</given-names></name>
<name><surname>Poirot</surname><given-names>O</given-names></name>
<name><surname>Pertin</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Transcriptional and functional profiles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain</article-title>. <source>Mol Cell Neurosci</source>. <year>2008</year>;<volume>37</volume>:<fpage>196</fpage>-<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010394852">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pertin</surname><given-names>M</given-names></name>
<name><surname>Ji</surname><given-names>RR</given-names></name>
<name><surname>Berta</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Upregulation of the voltage-gated sodium channel beta 2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons</article-title>. <source>J Neurosci</source>. <year>2005</year>;<volume>25</volume>:<fpage>10970</fpage>-<lpage>10980</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010394852">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lai</surname><given-names>J</given-names></name>
<name><surname>Porreca</surname><given-names>F</given-names></name>
<name><surname>Hunter</surname><given-names>JC</given-names></name>
<name><surname>Gold</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Voltage gated sodium channels and hyperalgesia</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>2004</year>;<volume>44</volume>:<fpage>371</fpage>-<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr16-0091270010394852">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coderre</surname><given-names>TJ</given-names></name>
<name><surname>Katz</surname><given-names>J</given-names></name>
<name><surname>Vaccarino</surname><given-names>AL</given-names></name>
<name><surname>Melzack</surname><given-names>R</given-names></name>
</person-group>. <article-title>Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence</article-title>. <source>Pain</source>. <year>1993</year>;<volume>52</volume>:<fpage>259</fpage>-<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr17-0091270010394852">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>LM</given-names></name>
<name><surname>Lu</surname><given-names>Y</given-names></name>
<name><surname>Crofford</surname><given-names>LJ</given-names></name>
<etal/>
</person-group>. <article-title>A double-blind, multicentre trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder</article-title>. <source>Arthritis Rheum</source>. <year>2004</year>;<volume>50</volume>:<fpage>2974</fpage>-<lpage>2984</lpage>.</citation>
</ref>
<ref id="bibr18-0091270010394852">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crofford</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Pharmaceutical treatment options for fibromyalgia</article-title>. <source>Curr Rheumatol Rep</source>. <year>2004</year>;<volume>6</volume>:<fpage>274</fpage>-<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr19-0091270010394852">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woolf</surname><given-names>CJ</given-names></name>
</person-group>. <article-title>Evidence for a central component of post-injury pain hypersensitivity</article-title>. <source>Nature</source>. <year>1983</year>;<volume>306</volume>:<fpage>686</fpage>-<lpage>688</lpage>.</citation>
</ref>
<ref id="bibr20-0091270010394852">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cardenas</surname><given-names>DD</given-names></name>
<name><surname>Warms</surname><given-names>CA</given-names></name>
<name><surname>Turner</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial</article-title>. <source>Pain</source>. <year>2002</year>;<volume>96</volume>:<fpage>365</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr21-0091270010394852">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sawnyok</surname><given-names>J</given-names></name>
<name><surname>Esser</surname><given-names>MJ</given-names></name>
<name><surname>Reid</surname><given-names>AR</given-names></name>
</person-group>. <article-title>Antidepressants as analgesics: an overview of central and peripheral mechanisms of action</article-title>. <source>J Psychiatry Neurosci</source>. <year>2001</year>;<volume>26</volume>:<fpage>21</fpage>-<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr22-0091270010394852">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gray</surname><given-names>AM</given-names></name>
<name><surname>Pache</surname><given-names>DM</given-names></name>
<name><surname>Sewell</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Do alpha2-adrenoceptors play a role in the antinociceptive mechanism of action of antidepressant compounds?</article-title> <source>Eur J Pharmacol</source>. <year>1999</year>;<volume>378</volume>:<fpage>161</fpage>-<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr23-0091270010394852">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eschalier</surname><given-names>A</given-names></name>
<name><surname>Montastruc</surname><given-names>JL</given-names></name>
<name><surname>Devoize</surname><given-names>JL</given-names></name>
<name><surname>Rigal</surname><given-names>F</given-names></name>
<name><surname>Gaillard-Plaza</surname><given-names>G</given-names></name>
<name><surname>Pechadre</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Influence of naloxone and methysergide on the analgesic effect of clomipramine in rats</article-title>. <source>Eur J Pharmacol</source>. <year>1981</year>;<volume>74</volume>:<fpage>1</fpage>-<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr24-0091270010394852">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yokogawa</surname><given-names>F</given-names></name>
<name><surname>Kiuchi</surname><given-names>Y</given-names></name>
<name><surname>Ishikawa</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>An investigation of monoamine receptors involved in antinociceptive effects of antidepressants</article-title>. <source>Anesth Analg</source>. <year>2002</year>;<volume>95</volume>:<fpage>163</fpage>-<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr25-0091270010394852">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mico</surname><given-names>JA</given-names></name>
<name><surname>Gibert-Rahola</surname><given-names>J</given-names></name>
<name><surname>Casas</surname><given-names>J</given-names></name>
<name><surname>Rojas</surname><given-names>O</given-names></name>
<name><surname>Serrano</surname><given-names>MI</given-names></name>
<name><surname>Serrano</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Implication of b1- and b2-adrenergic receptors in the antinociceptive effect of tricyclic antidepressants</article-title>. <source>Eur Neuropsychopharmacol</source>. <year>1997</year>;<volume>7</volume>:<fpage>139</fpage>-<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr26-0091270010394852">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cai</surname><given-names>Z</given-names></name>
<name><surname>McCaslin</surname><given-names>PP</given-names></name>
</person-group>. <article-title>Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainite- and N-methyl-D-aspartate-induced intracellular Ca<sup>2+</sup> levels in neuronal culture</article-title>. <source>Eur J Pharmacol</source>. <year>1992</year>;<volume>219</volume>:<fpage>53</fpage>-<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr27-0091270010394852">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skolnick</surname><given-names>P</given-names></name>
<name><surname>Layer</surname><given-names>RT</given-names></name>
<name><surname>Popik</surname><given-names>P</given-names></name>
<name><surname>Nowak</surname><given-names>G</given-names></name>
<name><surname>Paul</surname><given-names>IA</given-names></name>
<name><surname>Trullas</surname><given-names>R</given-names></name>
</person-group>. <article-title>Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression</article-title>. <source>Pharmacopsychiatry</source>. <year>1996</year>;<volume>29</volume>:<fpage>23</fpage>-<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr28-0091270010394852">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ogata</surname><given-names>N</given-names></name>
<name><surname>Yoshii</surname><given-names>M</given-names></name>
<name><surname>Narahashi</surname><given-names>T</given-names></name>
</person-group>. <article-title>Psychotropic drugs block voltage-gated ion channels in neuroblastoma cells</article-title>. <source>Brain Res</source>. <year>1989</year>;<volume>476</volume>:<fpage>140</fpage>-<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr29-0091270010394852">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sudoh</surname><given-names>Y</given-names></name>
<name><surname>Cahoon</surname><given-names>EE</given-names></name>
<name><surname>Gerner</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Tricyclic antidepressants as long-acting local anesthetics</article-title>. <source>Pain</source>. <year>2003</year>;<volume>103</volume>:<fpage>49</fpage>-<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr30-0091270010394852">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Antkiewicz-Michaluk</surname><given-names>L</given-names></name>
<name><surname>Romanska</surname><given-names>I</given-names></name>
<name><surname>Michaluk</surname><given-names>J</given-names></name>
<name><surname>Vetulani</surname><given-names>J</given-names></name>
</person-group>. <article-title>Role of calcium channels in effects of antidepressant drugs on responsiveness to pain</article-title>. <source>Psychopharmacology (Berl)</source>. <year>1991</year>;<volume>105</volume>:<fpage>269</fpage>-<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr31-0091270010394852">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galeotti</surname><given-names>N</given-names></name>
<name><surname>Ghelardini</surname><given-names>C</given-names></name>
<name><surname>Bartolini</surname><given-names>A</given-names></name>
</person-group>. <article-title>Involvement of potassium channels in amitriptyline and clomipramine analgesia</article-title>. <source>Neuropharmacology</source>. <year>2001</year>;<volume>40</volume>:<fpage>75</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr32-0091270010394852">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sawynok</surname><given-names>J</given-names></name>
<name><surname>Reid</surname><given-names>AR</given-names></name>
<name><surname>Liu</surname><given-names>XJ</given-names></name>
<name><surname>Parkinson</surname><given-names>FE</given-names></name>
</person-group>. <article-title>Amitriptyline enhances extracellular tissue levels of adenosine in the rat hindpaw and inhibits adenosine uptake</article-title>. <source>Eur J Pharmacol</source>. <year>2005</year>;<volume>518</volume>:<fpage>116</fpage>-<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr33-0091270010394852">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McCarson</surname><given-names>KE</given-names></name>
<name><surname>Duric</surname><given-names>V</given-names></name>
<name><surname>Reisman</surname><given-names>SA</given-names></name>
<name><surname>Winter</surname><given-names>M</given-names></name>
<name><surname>Enna</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>GABAB receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants</article-title>. <source>Brain Res</source>. <year>2006</year>;<volume>1068</volume>:<fpage>109</fpage>-<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr34-0091270010394852">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stein</surname><given-names>C</given-names></name>
</person-group>. <article-title>The control of pain in peripheral tissue by opioids</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>332</volume>:<fpage>1685</fpage>-<lpage>1690</lpage>.</citation>
</ref>
<ref id="bibr35-0091270010394852">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gray</surname><given-names>AM</given-names></name>
<name><surname>Spencer</surname><given-names>PS</given-names></name>
<name><surname>Sewell</surname><given-names>RD</given-names></name>
</person-group>. <article-title>The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds</article-title>. <source>Br J Pharmacol</source>. <year>1998</year>;<volume>124</volume>:<fpage>669</fpage>-<lpage>674</lpage>.</citation>
</ref>
<ref id="bibr36-0091270010394852">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yaron</surname><given-names>I</given-names></name>
<name><surname>Shirazi</surname><given-names>I</given-names></name>
<name><surname>Judovich</surname><given-names>R</given-names></name>
<name><surname>Levartovsky</surname><given-names>D</given-names></name>
<name><surname>Caspi</surname><given-names>D</given-names></name>
<name><surname>Yaron</surname><given-names>M</given-names></name>
</person-group>. <article-title>Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures</article-title>. <source>Arthritis Rheum</source>. <year>1999</year>;<volume>42</volume>:<fpage>2561</fpage>-<lpage>2568</lpage>.</citation>
</ref>
<ref id="bibr37-0091270010394852">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ignatowski</surname><given-names>TA</given-names></name>
<name><surname>Sud</surname><given-names>R</given-names></name>
<name><surname>Reynolds</surname><given-names>JL</given-names></name>
<name><surname>Knight</surname><given-names>PR</given-names></name>
<name><surname>Spengler</surname><given-names>RN</given-names></name>
</person-group>. <article-title>The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-a (TNF)</article-title>. <source>Neuropharmacology</source>. <year>2005</year>;<volume>48</volume>:<fpage>448</fpage>-<lpage>460</lpage>.</citation>
</ref>
<ref id="bibr38-0091270010394852">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verdu</surname><given-names>B</given-names></name>
<name><surname>Decosterd</surname><given-names>I</given-names></name>
<name><surname>Buclin</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Antidepressants for the treatment of chronic pain. Drugs</article-title> <year>2008</year>;<volume>68</volume>:<fpage>(18):2611</fpage>-<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr39-0091270010394852">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perrot</surname><given-names>S</given-names></name>
<name><surname>Javier</surname><given-names>RM</given-names></name>
<name><surname>Marty</surname><given-names>M</given-names></name>
<name><surname>Le Jeunne</surname><given-names>C</given-names></name>
<name><surname>Laroche</surname><given-names>F</given-names></name>
</person-group>. <article-title>Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies</article-title>. <source>Rheumatology (Oxford)</source>. <year>2008</year>;<volume>47</volume>:<fpage>1117</fpage>-<lpage>1123</lpage>.</citation>
</ref>
<ref id="bibr40-0091270010394852">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kieburtz</surname><given-names>K</given-names></name>
<name><surname>Simpson</surname><given-names>D</given-names></name>
<name><surname>Yiannoutsos</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team</article-title>. <source>Neurology</source>. <year>1998</year>;<volume>51</volume>:<fpage>1682</fpage>-<lpage>1688</lpage>.</citation>
</ref>
<ref id="bibr41-0091270010394852">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mercadante</surname><given-names>S</given-names></name>
<name><surname>Arcuri</surname><given-names>E</given-names></name>
<name><surname>Tirelli</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study</article-title>. <source>Tumor</source>. <year>2002</year>;<volume>88</volume>:<fpage>239</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr42-0091270010394852">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Robinson</surname><given-names>LR</given-names></name>
<name><surname>Czerniecki</surname><given-names>JM</given-names></name>
<name><surname>Ehde</surname><given-names>DM</given-names></name>
<etal/>
</person-group>. <article-title>Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2004</year>;<volume>85</volume>:<fpage>1</fpage>-<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr43-0091270010394852">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Max</surname><given-names>MB</given-names></name>
<name><surname>Culnane</surname><given-names>M</given-names></name>
<name><surname>Schafer</surname><given-names>SC</given-names></name>
<etal/>
</person-group>. <article-title>Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood</article-title>. <source>Neurology</source>. <year>1987</year>;<volume>37</volume>:<fpage>589</fpage>-<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr44-0091270010394852">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Max</surname><given-names>MB</given-names></name>
</person-group>. <article-title>Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial</article-title>. <source>Pain</source>. <year>1991</year>;<volume>45</volume>:<fpage>3</fpage>-<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr45-0091270010394852">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saarto</surname><given-names>T</given-names></name>
<name><surname>Wiffen</surname><given-names>PJ</given-names></name>
</person-group>. Antidepressants for neuropathic pain. <source>Cochrane Database Syst Rev</source>. <year>2007</year>;<volume>4</volume>:<comment>CD005454</comment>.</citation>
</ref>
<ref id="bibr46-0091270010394852">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salerno</surname><given-names>SM</given-names></name>
<name><surname>Browning</surname><given-names>R</given-names></name>
<name><surname>Jackson</surname><given-names>JL</given-names></name>
</person-group>. <article-title>The effect of antidepressant treatment on chronic back pain: a meta-analysis</article-title>. <source>Arch Intern Med</source>. <year>2002</year>;<volume>162</volume>:<fpage>19</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr47-0091270010394852">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Onghena</surname><given-names>P</given-names></name>
<name><surname>Van Houdenhove</surname><given-names>B</given-names></name>
</person-group>. <article-title>Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies</article-title>. <source>Pain</source>. <year>1992</year>;<volume>49</volume>:<fpage>205</fpage>-<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr48-0091270010394852">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raja</surname><given-names>SN</given-names></name>
<name><surname>Haythornthwaite</surname><given-names>JA</given-names></name>
<name><surname>Pappagallo</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Opioids versus antidepressants in postherpetic neuralgia. A randomized, placebo-controlled trial</article-title>. <source>Neurology</source>. <year>2002</year>;<volume>59</volume>:<fpage>1015</fpage>-<lpage>1021</lpage>.</citation>
</ref>
<ref id="bibr49-0091270010394852">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sindrup</surname><given-names>SH</given-names></name>
<name><surname>Bach</surname><given-names>FW</given-names></name>
<name><surname>Madsen</surname><given-names>C</given-names></name>
<name><surname>Gram</surname><given-names>LF</given-names></name>
<name><surname>Jensen</surname><given-names>TS</given-names></name>
</person-group>. <article-title>Venlafaxine versus imipramine in painful polyneuropathy: a randomized controlled trial</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>60</volume>:<fpage>1284</fpage>-<lpage>1289</lpage>.</citation>
</ref>
<ref id="bibr50-0091270010394852">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Max</surname><given-names>MB</given-names></name>
<name><surname>Lynch</surname><given-names>SA</given-names></name>
<name><surname>Muir</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy</article-title>. <source>N Engl J Med</source>. <year>1992</year>;<volume>326</volume>:<fpage>1250</fpage>-<lpage>1256</lpage>.</citation>
</ref>
<ref id="bibr51-0091270010394852">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rowbotham</surname><given-names>MC</given-names></name>
<name><surname>Goli</surname><given-names>V</given-names></name>
<name><surname>Kunz</surname><given-names>NR</given-names></name>
<etal/>
</person-group>. <article-title>Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study</article-title>. <source>Pain</source>. <year>2004</year>;<volume>110</volume>:<fpage>697</fpage>-<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr52-0091270010394852">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>DJ</given-names></name>
<name><surname>Lu</surname><given-names>Y</given-names></name>
<name><surname>Detke</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>. <article-title>Duloxetine vs placebo in patients with painful diabetic neuropathy</article-title>. <source>Pain</source>. <year>2005</year>;<volume>116</volume>:<fpage>109</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr53-0091270010394852">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wernicke</surname><given-names>JF</given-names></name>
<name><surname>Pritchett</surname><given-names>YL</given-names></name>
<name><surname>D’Souza</surname><given-names>DM</given-names></name>
<etal/>
</person-group>. <article-title>A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>67</volume>:<fpage>1411</fpage>-<lpage>1420</lpage>.</citation>
</ref>
<ref id="bibr54-0091270010394852">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Norregard</surname><given-names>J</given-names></name>
<name><surname>Volkmann</surname><given-names>H</given-names></name>
<name><surname>Danneskiold-Samsoe</surname><given-names>B</given-names></name>
</person-group>. <article-title>A randomized controlled study of citalopram in the treatment of fibromyalgia</article-title>. <source>Pain</source>. <year>1995</year>;<volume>61</volume>:<fpage>445</fpage>-<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr55-0091270010394852">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heymann</surname><given-names>RE</given-names></name>
<name><surname>Helfenstein</surname><given-names>M</given-names></name>
<name><surname>Feldman</surname><given-names>D</given-names></name>
</person-group>. <article-title>A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia</article-title>. <source>Clin Exp Rheumatol</source>. <year>2001</year>;<volume>19</volume>:<fpage>697</fpage>-<lpage>702</lpage>.</citation>
</ref>
<ref id="bibr56-0091270010394852">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>LM</given-names></name>
<name><surname>Hess</surname><given-names>EV</given-names></name>
<name><surname>Hudson</surname><given-names>JI</given-names></name>
<name><surname>Welge</surname><given-names>JA</given-names></name>
<name><surname>Berno</surname><given-names>SE</given-names></name>
<name><surname>Keck</surname><given-names>PE</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia</article-title>. <source>Am J Med</source>. <year>2002</year>;<volume>112</volume>:<fpage>191</fpage>-<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr57-0091270010394852">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mease</surname><given-names>PJ</given-names></name>
<name><surname>Clauw</surname><given-names>DJ</given-names></name>
<name><surname>Gendreau</surname><given-names>RM</given-names></name>
<etal/>
</person-group>. <article-title>The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial</article-title>. <source>J Rheumatol</source>. <year>2009</year>;<volume>36</volume>:<fpage>398</fpage>-<lpage>409</lpage>.</citation>
</ref>
<ref id="bibr58-0091270010394852">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Malley</surname><given-names>PG</given-names></name>
<name><surname>Balden</surname><given-names>E</given-names></name>
<name><surname>Tomkins</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Treatment of fibromyalgia with antidepressants: a meta-analysis</article-title>. <source>J Gen Intern Med</source>. <year>2000</year>;<volume>15</volume>:<fpage>659</fpage>-<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr59-0091270010394852">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dickens</surname><given-names>C</given-names></name>
<name><surname>Jayson</surname><given-names>M</given-names></name>
<name><surname>Sutton</surname><given-names>C</given-names></name>
<name><surname>Creed</surname><given-names>F</given-names></name>
</person-group>. <article-title>The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain</article-title>. <source>Psychosomatics</source>. <year>2000</year>;<volume>41</volume>:<fpage>490</fpage>-<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr60-0091270010394852">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katz</surname><given-names>J</given-names></name>
<name><surname>Pennella-Vaughan</surname><given-names>J</given-names></name>
<name><surname>Hetzel</surname><given-names>RD</given-names></name>
<etal/>
</person-group>. <article-title>A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain</article-title>. <source>J Pain</source>. <year>2005</year>;<volume>6</volume>:<fpage>656</fpage>-<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr61-0091270010394852">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Staiger</surname><given-names>TO</given-names></name>
<name><surname>Gaster</surname><given-names>B</given-names></name>
<name><surname>Sullivan</surname><given-names>MD</given-names></name>
<etal/>
</person-group>. <article-title>Systematic review of antidepressants in the treatment of chronic low back pain</article-title>. <source>Spine</source>. <year>2003</year>;<volume>28</volume>:<fpage>2540</fpage>-<lpage>2545</lpage>.</citation>
</ref>
<ref id="bibr62-0091270010394852">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jenkins</surname><given-names>DG</given-names></name>
<name><surname>Ebbutt</surname><given-names>AF</given-names></name>
<name><surname>Evans</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Tofranil in the treatment of low back pain</article-title>. <source>J Int Med Res</source>. <year>1976</year>;<volume>4</volume>:<fpage>28</fpage>-<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr63-0091270010394852">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ash</surname><given-names>G</given-names></name>
<name><surname>Dickens</surname><given-names>CM</given-names></name>
<name><surname>Creed</surname><given-names>FH</given-names></name>
<name><surname>Jayson</surname><given-names>MI</given-names></name>
<name><surname>Tomenson</surname><given-names>B</given-names></name>
</person-group>. <article-title>The effects of dothiepin on subjects with rheumatoid arthritis and depression</article-title>. <source>Rheumatology</source>. <year>1999</year>;<volume>38</volume>:<fpage>959</fpage>-<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr64-0091270010394852">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koh</surname><given-names>WH</given-names></name>
<name><surname>Pande</surname><given-names>I</given-names></name>
<name><surname>Samuels</surname><given-names>A</given-names></name>
<name><surname>Jones</surname><given-names>SD</given-names></name>
<name><surname>Calin</surname><given-names>A</given-names></name>
</person-group>. <article-title>Low-dose amitriptyline in ankylosing spondylitis: a short-term, double-blind, placebo-controlled study</article-title>. <source>J Rheumatol</source>. <year>1997</year>;<volume>4</volume>:<fpage>2158</fpage>-<lpage>2161</lpage>.</citation>
</ref>
<ref id="bibr65-0091270010394852">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bryson</surname><given-names>HM</given-names></name>
<name><surname>Wilde</surname><given-names>MI</given-names></name>
</person-group>. <article-title>Amitriptyline: a review of its pharmacological properties and the therapeutic use in chronic pain states</article-title>. <source>Drugs Aging</source>. <year>1996</year>;<volume>8</volume>:<fpage>459</fpage>-<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr66-0091270010394852">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galer</surname><given-names>BS</given-names></name>
</person-group>. <article-title>Neuropathic pain of peripheral origin: advances in pharmacologic treatment</article-title>. <source>Neurology</source>. <year>1995</year>;<volume>45</volume>(<issue>Suppl 9</issue>):<fpage>17</fpage>-<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr67-0091270010394852">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Attal</surname><given-names>N</given-names></name>
<name><surname>Cruccua</surname><given-names>G</given-names></name>
<name><surname>Haanpaa</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>EFNS guidelines on pharmacological treatment of neuropathic pain</article-title>. <source>Eur J Neurol</source>. <year>2006</year>;<volume>13</volume>:<fpage>1153</fpage>-<lpage>1169</lpage>.</citation>
</ref>
<ref id="bibr68-0091270010394852">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leijon</surname><given-names>G</given-names></name>
<name><surname>Boivie</surname><given-names>J</given-names></name>
</person-group>. <article-title>Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine</article-title>. <source>Pain</source>. <year>1989</year>;<volume>36</volume>:<fpage>27</fpage>-<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr69-0091270010394852">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finnerup</surname><given-names>NB</given-names></name>
<name><surname>Otto</surname><given-names>M</given-names></name>
<name><surname>McQuay</surname><given-names>HJ</given-names></name>
<name><surname>Jensen</surname><given-names>TS</given-names></name>
<name><surname>Sindrup</surname><given-names>SH</given-names></name>
</person-group>. <article-title>Algorithm for neuropathic pain treatment: an evidence based proposal</article-title>. <source>Pain</source>. <year>2005</year>;<volume>118</volume>:<fpage>289</fpage>-<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr70-0091270010394852">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldenberg</surname><given-names>DL</given-names></name>
<name><surname>Felson</surname><given-names>DT</given-names></name>
<name><surname>Dinerman</surname><given-names>H</given-names></name>
</person-group>. <article-title>A randomised, controlled trial of amitriptyline and naproxene in the treatment of patients with fibromyalgia</article-title>. <source>Arthritis Rheum</source>. <year>1986</year>;<volume>29</volume>:<fpage>1371</fpage>-<lpage>1377</lpage>.</citation>
</ref>
<ref id="bibr71-0091270010394852">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carette</surname><given-names>S</given-names></name>
<name><surname>McCain</surname><given-names>GA</given-names></name>
<name><surname>Bell</surname><given-names>DA</given-names></name>
<name><surname>Fam</surname><given-names>AG</given-names></name>
</person-group>. <article-title>Evaluation of amitriptyline in primary fibrositis. A double-blinded, placebo-controlled study</article-title>. <source>Arthritis Rheum</source>. <year>1986</year>;<volume>29</volume>:<fpage>655</fpage>-<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr72-0091270010394852">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bibolotti</surname><given-names>E</given-names></name>
<name><surname>Borghi</surname><given-names>C</given-names></name>
<name><surname>Pasculli</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>The management of fibrositis. A double-blind comparison of maprotiline (Ludiomil) clorimipramine and placebo</article-title>. <source>Clin Trials J</source>. <year>1986</year>;<volume>23</volume>:<fpage>269</fpage>-<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr73-0091270010394852">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caruso</surname><given-names>I</given-names></name>
<name><surname>Sarzi Puttini</surname><given-names>PC</given-names></name>
<name><surname>Boccassini</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome</article-title>. <source>J Int Med Res</source>. <year>1987</year>;<volume>15</volume>:<fpage>154</fpage>-<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr74-0091270010394852">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>RM</given-names></name>
<name><surname>Gatter</surname><given-names>RA</given-names></name>
<name><surname>Campbell</surname><given-names>SM</given-names></name>
<name><surname>Andrews</surname><given-names>RP</given-names></name>
<name><surname>Clark</surname><given-names>SR</given-names></name>
<name><surname>Scarola</surname><given-names>JA</given-names></name>
</person-group>. <article-title>A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study</article-title>. <source>Arthritis Rheum</source>. <year>1988</year>;<volume>31</volume>:<fpage>1535</fpage>-<lpage>1542</lpage>.</citation>
</ref>
<ref id="bibr75-0091270010394852">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamaty</surname><given-names>D</given-names></name>
<name><surname>Valentine</surname><given-names>JL</given-names></name>
<name><surname>Howard</surname><given-names>R</given-names></name>
<name><surname>Howard</surname><given-names>CW</given-names></name>
<name><surname>Wakefield</surname><given-names>V</given-names></name>
<name><surname>Patten</surname><given-names>MS</given-names></name>
</person-group>. <article-title>The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo: a 5-month study</article-title>. <source>J Rheumatol</source>. <year>1989</year>;<volume>19</volume>(<issue>Suppl</issue>): <fpage>164</fpage>-<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr76-0091270010394852">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scudds</surname><given-names>RA</given-names></name>
<name><surname>McCain</surname><given-names>GA</given-names></name>
<name><surname>Rollman</surname><given-names>GB</given-names></name>
<name><surname>Harth</surname><given-names>M</given-names></name>
</person-group>. <article-title>Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline</article-title>. <source>J Rheumatol</source>. <year>1989</year>;<volume>19</volume>(<issue>Suppl</issue>):<fpage>98</fpage>-<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr77-0091270010394852">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quimby</surname><given-names>LG</given-names></name>
<name><surname>Gratwick</surname><given-names>GM</given-names></name>
<name><surname>Whitney</surname><given-names>CD</given-names></name>
<name><surname>Block</surname><given-names>SR</given-names></name>
</person-group>. <article-title>A randomized trial of cyclobenzaprine for the treatment of fibromyalgia</article-title>. <source>J Rheumatol</source>. <year>1989</year>;<volume>19</volume>(<issue>Suppl</issue>):<fpage>140</fpage>-<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr78-0091270010394852">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>WJ</given-names></name>
<name><surname>Moldofsky</surname><given-names>H</given-names></name>
<name><surname>Saskin</surname><given-names>P</given-names></name>
<name><surname>Lue</surname><given-names>FA</given-names></name>
</person-group>. <article-title>The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia</article-title>. <source>J Rheumatol</source>. <year>1991</year>;<volume>18</volume>:<fpage>452</fpage>-<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr79-0091270010394852">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fossaluzza</surname><given-names>V</given-names></name>
<name><surname>De Vita</surname><given-names>S</given-names></name>
</person-group>. <article-title>Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome</article-title>. <source>Int J Clin Pharm Res</source>. <year>1992</year>;<volume>XII</volume>:<fpage>99</fpage>-<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr80-0091270010394852">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carette</surname><given-names>S</given-names></name>
<name><surname>Bell</surname><given-names>MJ</given-names></name>
<name><surname>Reynolds</surname><given-names>WJ</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia</article-title>. <source>Arthritis Rheum</source>. <year>1994</year>;<volume>37</volume>:<fpage>32</fpage>-<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr81-0091270010394852">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cantini</surname><given-names>F</given-names></name>
<name><surname>Bellandi</surname><given-names>F</given-names></name>
<name><surname>Niccoli</surname><given-names>L</given-names></name>
<name><surname>Di Munno</surname><given-names>O</given-names></name>
</person-group>. <article-title>Fluoxetina associata a ciclobenzaprina nel trattamento della fibromialgia</article-title>. <source>Minerva Med</source>. <year>1994</year>;<volume>85</volume>:<fpage>97</fpage>-<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr82-0091270010394852">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldenberg</surname><given-names>D</given-names></name>
<name><surname>Mayskiy</surname><given-names>M</given-names></name>
<name><surname>Mossey</surname><given-names>C</given-names></name>
<name><surname>Ruthaser</surname><given-names>R</given-names></name>
<name><surname>Schmid</surname><given-names>C</given-names></name>
</person-group>. <article-title>A randomized, doubleblind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia</article-title>. <source>Arthritis Rheum</source>. <year>1996</year>;<volume>39</volume>:<fpage>1852</fpage>-<lpage>1859</lpage>.</citation>
</ref>
<ref id="bibr83-0091270010394852">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ginsberg</surname><given-names>F</given-names></name>
<name><surname>Mancaux</surname><given-names>A</given-names></name>
<name><surname>Joos</surname><given-names>E</given-names></name>
<name><surname>Vanhove</surname><given-names>P</given-names></name>
<name><surname>Famaey</surname><given-names>JP</given-names></name>
</person-group>. <article-title>A randomized placebo controlled trial of sustained-release amitriptyline in primary fibromyalgia</article-title>. <source>J Musculoskel Pain</source>. <year>1996</year>;<volume>4</volume>:<fpage>37</fpage>-<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr84-0091270010394852">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hannonen</surname><given-names>P</given-names></name>
<name><surname>Malminiemi</surname><given-names>K</given-names></name>
<name><surname>Yli-Kerttula</surname><given-names>U</given-names></name>
<name><surname>Isomeri</surname><given-names>R</given-names></name>
<name><surname>Roponen</surname><given-names>P</given-names></name>
</person-group>. <article-title>A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder</article-title>. <source>Br J Rheumatol</source>. <year>1998</year>;<volume>37</volume>:<fpage>1279</fpage>-<lpage>1286</lpage>.</citation>
</ref>
<ref id="bibr85-0091270010394852">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>LM</given-names></name>
<name><surname>Keck</surname><given-names>PE</given-names><suffix>Jr</suffix></name>
<name><surname>Welge</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Antidepressant treatment of fibromyalgia: a meta-analysis and review</article-title>. <source>Psychosomatics</source>. <year>2000</year>;<volume>41</volume>:<fpage>104</fpage>-<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr86-0091270010394852">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chou</surname><given-names>R</given-names></name>
<name><surname>Huffman</surname><given-names>LH</given-names></name>
</person-group>. <article-title>Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians Clinical practice guideline</article-title>. <source>Ann Intern Med</source>. <year>2007</year>;<volume>147</volume>:<fpage>505</fpage>-<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr87-0091270010394852">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schnitzer</surname><given-names>TJ</given-names></name>
<name><surname>Ferraro</surname><given-names>A</given-names></name>
<name><surname>Hunsche</surname><given-names>E</given-names></name>
<name><surname>Kong</surname><given-names>SX</given-names></name>
</person-group>. <article-title>A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain</article-title>. <source>Pain Symptom Manage</source>. <year>2004</year>;<volume>28</volume>:<fpage>72</fpage>-<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr88-0091270010394852">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stein</surname><given-names>D</given-names></name>
<name><surname>Peri</surname><given-names>T</given-names></name>
<name><surname>Edelstein</surname><given-names>E</given-names></name>
<name><surname>Elizur</surname><given-names>A</given-names></name>
<name><surname>Floman</surname><given-names>Y</given-names></name>
</person-group>. <article-title>The efficacy of amitriptyline and acetaminophen in the management of acute low back pain</article-title>. <source>Psychosomatics</source>. <year>1996</year>;<volume>36</volume>:<fpage>63</fpage>-<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr89-0091270010394852">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Atkinson</surname><given-names>JH</given-names></name>
<name><surname>Slater</surname><given-names>MA</given-names></name>
<name><surname>Williams</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. <article-title>A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain</article-title>. <source>Pain</source>. <year>1998</year>;<volume>76</volume>:<fpage>287</fpage>-<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr90-0091270010394852">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Atkinson</surname><given-names>JH</given-names></name>
<name><surname>Slater</surname><given-names>MA</given-names></name>
<name><surname>Wahlgren</surname><given-names>DR</given-names></name>
<etal/>
</person-group>. <article-title>Effects of nor-adrenergic and serotonergic antidepressants on chronic low back pain intensity</article-title>. <source>Pain</source>. <year>1999</year>;<volume>83</volume>:<fpage>137</fpage>-<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr91-0091270010394852">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>EH</given-names></name>
<name><surname>Katon</surname><given-names>W</given-names></name>
<name><surname>Von Korff</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial</article-title>. <source>J Am Med Assoc</source>. <year>2003</year>;<volume>290</volume>:<fpage>2428</fpage>-<lpage>2429</lpage>.</citation>
</ref>
<ref id="bibr92-0091270010394852">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McQuay</surname><given-names>HJ</given-names></name>
<name><surname>Carroll</surname><given-names>D</given-names></name>
<name><surname>Glynn</surname><given-names>CJ</given-names></name>
</person-group>. <article-title>Dose-response for analgesic effect of amitriptyline in chronic pain</article-title>. <source>Anaesthesia</source>. <year>1993</year>;<volume>48</volume>:<fpage>281</fpage>-<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr93-0091270010394852">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wheatley</surname><given-names>D</given-names></name>
</person-group>. <article-title>Antidepressants in elderly arthritics</article-title>. <source>Practitioner</source>. <year>1986</year>;<volume>230</volume>:<fpage>477</fpage>-<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr94-0091270010394852">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tomkins</surname><given-names>GE</given-names></name>
<name><surname>Jackson</surname><given-names>JL</given-names></name>
<name><surname>O’Malley</surname><given-names>PG</given-names></name>
<etal/>
</person-group>. <article-title>Treatment of chronic headache with antidepressants: a meta-analysis</article-title>. <source>Am J Med</source>. <year>2001</year>;<volume>111</volume>:<fpage>54</fpage>-<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr95-0091270010394852">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silberstein</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Preventive treatment of migraine</article-title>. <source>Trends Pharmacol Sci</source>. <year>2006</year>;<volume>27</volume>:<fpage>410</fpage>-<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr96-0091270010394852">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarchielli</surname><given-names>P</given-names></name>
<name><surname>Mancini</surname><given-names>ML</given-names></name>
<name><surname>Calabresi</surname><given-names>P</given-names></name>
</person-group>. <article-title>Practical considerations for the treatment of elderly patients with migraine</article-title>. <source>Drugs Aging</source>. <year>2006</year>;<volume>23</volume>:<fpage>461</fpage>-<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr97-0091270010394852">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderberg</surname><given-names>UA</given-names></name>
<name><surname>Marteinsdottir</surname><given-names>I</given-names></name>
<name><surname>von Knorring</surname><given-names>L</given-names></name>
</person-group>. <article-title>Citalopram in patients with fibromyalgia—a randomised, double-blind, placebo-controlled study</article-title>. <source>Eur J Pain</source>. <year>2000</year>;<volume>4</volume>:<fpage>27</fpage>-<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr98-0091270010394852">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geller</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Treatment of fibrositis with fluoxetine hydrochloride (Prozac)</article-title>. <source>Am J Med</source>. <year>1989</year>;<volume>87</volume>:<fpage>594</fpage>-<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr99-0091270010394852">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cortet</surname><given-names>B</given-names></name>
<name><surname>Houvenagel</surname><given-names>E</given-names></name>
<name><surname>Forzy</surname><given-names>G</given-names></name>
<name><surname>Vincent</surname><given-names>G</given-names></name>
<name><surname>Delcambre</surname><given-names>B</given-names></name>
</person-group>. <article-title>Evaluation of the effectiveness of serotonin (fluoxetine hydrochloride) treatment. Open study in fibromyalgia</article-title>. <source>Rev Rhum Mal Osteoartic</source>. <year>1992</year>;<volume>59</volume>:<fpage>497</fpage>-<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr100-0091270010394852">
<label>100.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolfe</surname><given-names>F</given-names></name>
<name><surname>Cathey</surname><given-names>MA</given-names></name>
<name><surname>Hawley</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>A double-blind placebo controlled trial of fluoxetine in fibromyalgia</article-title>. <source>Scand J Rheumatol</source>. <year>1994</year>;<volume>23</volume>:<fpage>255</fpage>-<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr101-0091270010394852">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ataoglu</surname><given-names>S</given-names></name>
<name><surname>Ataoglu</surname><given-names>A</given-names></name>
<name><surname>Erdoan</surname><given-names>F</given-names></name>
<name><surname>Sarac</surname><given-names>J</given-names></name>
</person-group>. <article-title>Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia</article-title>. <source>Turk J Med Sci</source>. <year>1997</year>;<volume>27</volume>:<fpage>535</fpage>-<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr102-0091270010394852">
<label>102.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patkar</surname><given-names>AA</given-names></name>
<name><surname>Masand</surname><given-names>PS</given-names></name>
<name><surname>Krulewicz</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>A randomized, controlled, trial of controlled-release paroxetine in fibromyalgia</article-title>. <source>Am J Med</source>. <year>2007</year>;<volume>120</volume>:<fpage>448</fpage>-<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr103-0091270010394852">
<label>103.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sindrup</surname><given-names>SH</given-names></name>
<name><surname>Gram</surname><given-names>LF</given-names></name>
<name><surname>Brosen</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms</article-title>. <source>Pain</source>. <year>1990</year>;<volume>42</volume>:<fpage>135</fpage>-<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr104-0091270010394852">
<label>104.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ciaramella</surname><given-names>A</given-names></name>
<name><surname>Grosso</surname><given-names>S</given-names></name>
<name><surname>Poli</surname><given-names>P</given-names></name>
</person-group>. <article-title>Fluoxetine versus fluvoxamine for treatment of chronic pain [in Italian]</article-title>. <source>Minerva Anestesiol</source>. <year>2000</year>;<volume>66</volume>:<fpage>55</fpage>-<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr105-0091270010394852">
<label>105.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maina</surname><given-names>G</given-names></name>
<name><surname>Vitalucci</surname><given-names>A</given-names></name>
<name><surname>Gandolfo</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study</article-title>. <source>J Clin Psychiatry</source>. <year>2002</year>;<volume>63</volume>:<fpage>38</fpage>-<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr106-0091270010394852">
<label>106.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sindrup</surname><given-names>SH</given-names></name>
<name><surname>Bjerre</surname><given-names>U</given-names></name>
<name><surname>Dejgaard</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy</article-title>. <source>Clin Pharmacol Ther</source>. <year>1992</year>;<volume>52</volume>:<fpage>547</fpage>-<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr107-0091270010394852">
<label>107.</label>
<citation citation-type="other">
<person-group person-group-type="author">
<name><surname>Moja</surname><given-names>PL</given-names></name>
<name><surname>Cusi</surname><given-names>C</given-names></name>
<name><surname>Sterzi</surname><given-names>RR</given-names></name>
<etal/>
</person-group>. <article-title>Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2005</year>;<volume>3</volume>:<comment>CD002919</comment>.</citation>
</ref>
<ref id="bibr108-0091270010394852">
<label>108.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lithner</surname><given-names>F</given-names></name>
</person-group>. <article-title>Venlafaxine in treatment of severe painful peripheral diabetic neuropathy</article-title>. <source>Diabetes Care</source>. <year>2000</year>;<volume>23</volume>:<fpage>1710</fpage>-<lpage>1711</lpage>.</citation>
</ref>
<ref id="bibr109-0091270010394852">
<label>109.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sumpton</surname><given-names>JE</given-names></name>
<name><surname>Moulin</surname><given-names>DE</given-names></name>
</person-group>. <article-title>Treatment of neuropathic pain with venlafaxine</article-title>. <source>Ann Pharmacother</source>. <year>2001</year>;<volume>35</volume>:<fpage>557</fpage>-<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr110-0091270010394852">
<label>110.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sayar</surname><given-names>K</given-names></name>
<name><surname>Aksu</surname><given-names>G</given-names></name>
<name><surname>Ak</surname><given-names>I</given-names></name>
<name><surname>Tosun</surname><given-names>M</given-names></name>
</person-group>. <article-title>Venlafaxine treatment of fibromyalgia</article-title>. <source>Ann Pharmacother</source>. <year>2003</year>;<volume>37</volume>:<fpage>1561</fpage>-<lpage>1565</lpage>.</citation>
</ref>
<ref id="bibr111-0091270010394852">
<label>111.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dwight</surname><given-names>MM</given-names></name>
<name><surname>Arnold</surname><given-names>LD</given-names></name>
<name><surname>O’Brien</surname><given-names>H</given-names></name>
<name><surname>Metzger</surname><given-names>R</given-names></name>
<name><surname>Morris-Park</surname><given-names>E</given-names></name>
<name><surname>Keck</surname><given-names>PE</given-names></name>
</person-group>. <article-title>An open trial of venlafaxine treatment of fibromyalgia</article-title>. <source>Psychosomatics</source>. <year>1998</year>;<volume>39</volume>:<fpage>14</fpage>-<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr112-0091270010394852">
<label>112.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>LM</given-names></name>
<name><surname>Rosen</surname><given-names>A</given-names></name>
<name><surname>Pritchett</surname><given-names>YL</given-names></name>
<etal/>
</person-group>. <article-title>A randomised, double-blind, placebo controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder</article-title>. <source>Pain</source>. <year>2005</year>;<volume>119</volume>:<fpage>5</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr113-0091270010394852">
<label>113.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clauw</surname><given-names>DJ</given-names></name>
<name><surname>Mease</surname><given-names>P</given-names></name>
<name><surname>Palmer</surname><given-names>RH</given-names></name>
<name><surname>Gendreau</surname><given-names>RM</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial</article-title>. <source>Clin Ther</source>. <year>2008</year>;<volume>30</volume>:<fpage>1988</fpage>-<lpage>2004</lpage>.</citation>
</ref>
<ref id="bibr114-0091270010394852">
<label>114.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ozyalcin</surname><given-names>SN</given-names></name>
<name><surname>Talu</surname><given-names>GK</given-names></name>
<name><surname>Kiziltan</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>The efficacy and safety of venlafaxine in the prophylaxis of migraine</article-title>. <source>Headache</source>. <year>2005</year>;<volume>45</volume>:<fpage>144</fpage>-<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr115-0091270010394852">
<label>115.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bulut</surname><given-names>S</given-names></name>
<name><surname>Berilgen</surname><given-names>MS</given-names></name>
<name><surname>Barar</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study</article-title>. <source>Clin Neurol Neurosurg</source>. <year>2004</year>;<volume>107</volume>:<fpage>44</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr116-0091270010394852">
<label>116.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pakulska</surname><given-names>W</given-names></name>
<name><surname>Czarnecka</surname><given-names>E</given-names></name>
</person-group>. <article-title>Influence of mianserin on the antinociceptive effect of morphine, metamizol and indomethacin in mice</article-title>. <source>Pharmacol Res</source>. <year>2002</year>;<volume>46</volume>:<fpage>415</fpage>-<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr117-0091270010394852">
<label>117.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sindrup</surname><given-names>SH</given-names></name>
<name><surname>Tuxen</surname><given-names>C</given-names></name>
<name><surname>Gram</surname><given-names>LF</given-names></name>
<etal/>
</person-group>. <article-title>Lack of effect of mianserin on the symptoms of diabetic neuropathy</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1992</year>;<volume>43</volume>:<fpage>251</fpage>-<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr118-0091270010394852">
<label>118.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Wei</surname><given-names>X</given-names></name>
<name><surname>Feng</surname><given-names>X</given-names></name>
<name><surname>Song</surname><given-names>J</given-names></name>
<name><surname>Hu</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name>
</person-group>. <article-title>Repeated administration of mirtazapine inhibits development of hyperalgesia/allodynia and activation of NF-kappaB in a rat model of neuropathic pain</article-title>. <source>Neurosci Lett</source>. <year>2008</year>;<volume>433</volume>:<fpage>33</fpage>-<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr119-0091270010394852">
<label>119.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freynhagen</surname><given-names>R</given-names></name>
<name><surname>Muth-Selbach</surname><given-names>U</given-names></name>
<name><surname>Lipfert</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>The effect of mirtazapine in patients with chronic pain and concomitant depression</article-title>. <source>Curr Med Res Opin</source>. <year>2006</year>;<volume>22</volume>:<fpage>257</fpage>-<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr120-0091270010394852">
<label>120.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pick</surname><given-names>CG</given-names></name>
<name><surname>Paul</surname><given-names>D</given-names></name>
<name><surname>Eison</surname><given-names>MS</given-names></name>
<name><surname>Pasternak</surname><given-names>GW</given-names></name>
</person-group>. <article-title>Potentiation of opioids analgesia by the antidepressant nefazodone</article-title>. <source>Eur J Pharmacol</source>. <year>1992</year>;<volume>211</volume>:<fpage>375</fpage>-<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr121-0091270010394852">
<label>121.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Baldessarini</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Drugs and the treatment of psychiatric disorders</article-title>. In: <person-group person-group-type="editor">
<name><surname>Goodman</surname><given-names>GA</given-names></name>
<name><surname>Rall</surname><given-names>TTW</given-names></name>
<name><surname>Nies</surname><given-names>AS</given-names></name>
<name><surname>Taylor</surname><given-names>P</given-names></name>
</person-group>, eds. <source>The Pharmacological Basis of Therapeutics</source>. <volume>Vol. 8</volume>. <publisher-loc>New York</publisher-loc>: <publisher-name>Pergamon Press</publisher-name>; <year>1990</year>:<fpage>383</fpage>-<lpage>435</lpage>.</citation>
</ref>
<ref id="bibr122-0091270010394852">
<label>122.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glassman</surname><given-names>AH</given-names></name>
<name><surname>Bigger</surname><given-names>JT</given-names></name>
</person-group>. <article-title>Cardiovascular effects of therapeutic doses of tricyclic antidepressants</article-title>. <source>Arch Gen Psychiatry</source>. <year>1981</year>;<volume>36</volume>:<fpage>815</fpage>-<lpage>819</lpage>.</citation>
</ref>
<ref id="bibr123-0091270010394852">
<label>123.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Eschalier</surname><given-names>A</given-names></name>
<name><surname>Ardid</surname><given-names>D</given-names></name>
<name><surname>Dubray</surname><given-names>C</given-names></name>
</person-group>. <article-title>Tricyclic and other antidepressants as analgesics</article-title>. In: <person-group person-group-type="editor">
<name><surname>Sawynok</surname><given-names>J</given-names></name>
<name><surname>Cowan</surname><given-names>A</given-names></name>
</person-group>, eds. <source>Novel Aspects of Pain Management: Opioids and Beyond</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Wiley-Liss</publisher-name>; <year>1999</year>;<fpage>303</fpage>-<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr124-0091270010394852">
<label>124.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McQuay</surname><given-names>HJ</given-names></name>
<name><surname>Tramèr</surname><given-names>M</given-names></name>
<name><surname>Nye</surname><given-names>BA</given-names></name>
<name><surname>Carroll</surname><given-names>D</given-names></name>
<name><surname>Wiffen</surname><given-names>PJ</given-names></name>
<name><surname>Moore</surname><given-names>RA</given-names></name>
</person-group>. <article-title>A systematic review of antidepressants in neuropathic pain</article-title>. <source>Pain</source>. <year>1996</year>;<volume>68</volume>:<fpage>217</fpage>-<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr125-0091270010394852">
<label>125.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rintala</surname><given-names>DH</given-names></name>
<name><surname>Holmes</surname><given-names>SA</given-names></name>
<name><surname>Courtade</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of the effectiveness of amitriptyline and gabapentin in chronic neuropathic pain in persons with spinal cord injury</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2007</year>;<volume>88</volume>:<fpage>1547</fpage>-<lpage>1560</lpage>.</citation>
</ref>
<ref id="bibr126-0091270010394852">
<label>126.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pancrazio</surname><given-names>JJ</given-names></name>
<name><surname>Kamatchi</surname><given-names>GL</given-names></name>
<name><surname>Roscoe</surname><given-names>AK</given-names></name>
<name><surname>Lynch</surname><given-names>C</given-names></name>
</person-group>. <article-title>Inhibition of neuronal Na+ channels by antidepressant drugs</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1998</year>;<volume>284</volume>:<fpage>208</fpage>-<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr127-0091270010394852">
<label>127.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrigan</surname><given-names>RA</given-names></name>
<name><surname>Brady</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>ECG abnormalities in tricyclic antidepressant ingestion</article-title>. <source>Am J Emerg Med</source>. <year>1999</year>;<volume>17</volume>:<fpage>387</fpage>-<lpage>393</lpage>.</citation>
</ref>
<ref id="bibr128-0091270010394852">
<label>128.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>BA</given-names></name>
<name><surname>Mittmann</surname><given-names>N</given-names></name>
<name><surname>Knowles</surname><given-names>SR</given-names></name>
<etal/>
</person-group>. <article-title>Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports</article-title>. <source>Can Med Assoc J</source>. <year>1996</year>;<volume>155</volume>:<fpage>519</fpage>-<lpage>527</lpage>.</citation>
</ref>
<ref id="bibr129-0091270010394852">
<label>129.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boyer</surname><given-names>EW</given-names></name>
<name><surname>Shannon</surname><given-names>M</given-names></name>
</person-group>. <article-title>The serotonin syndrome</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>1112</fpage>-<lpage>1120</lpage>.</citation>
</ref>
<ref id="bibr130-0091270010394852">
<label>130.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dworkin</surname><given-names>RH</given-names></name>
<name><surname>O’Connor</surname><given-names>AB</given-names></name>
<name><surname>Audette</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Recommendations for the pharmacological management of neuropathic pain: an overview and literature update</article-title>. <source>Mayo Clin Proc</source>. <year>2010</year>;<volume>85</volume>:<fpage>S3</fpage>-<lpage>S14</lpage>.</citation>
</ref>
<ref id="bibr131-0091270010394852">
<label>131.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenzweig</surname><given-names>TM</given-names></name>
<name><surname>Thomas</surname><given-names>TM</given-names></name>
</person-group>. <article-title>An update on fibromyalgia syndrome: the multimodal therapeutic approach</article-title>. <source>Am J Lifestyle Med</source>. <year>2009</year>;<volume>3</volume>:<fpage>226</fpage>-<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr132-0091270010394852">
<label>132.</label>
<citation citation-type="journal">
<collab>Practice Guidelines for Chronic Pain Management</collab>. <article-title>An updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine</article-title>. <source>Anesthesiology</source>. <year>2010</year>;<volume>112</volume>:<fpage>810</fpage>-<lpage>833</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>